Effect of vitamin K2 on the development of stress-induced osteopenia in a growing senescence-accelerated mouse prone 6 strain
Open Access
- 7 July 2015
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 10 (3) , 843-850
Abstract
Vitamin K2 (VK2) has been used as a therapeutic agent for osteoporosis, since it has been suggested to be able to reduce the frequency of fractures by improving bone quality; however, bone turnover is strictly regulated by various cytokines and hormones. In the present study, the effect of menaquinone-4 (MK-4) on bone turnover was investigated using the senescence-accelerated mouse prone 6 (SAMP6) strain. Since water-immersion restraint stress (WRS) causes a significant decrease in bone mineral density (BMD), WRS was used as the bone resorption model in the SAMP6 strain. Six-week-old SAMP6 male mice were divided into the following three groups: Control, WRS and WRS + MK-4. WRS was performed for 6 h per day, 5 times a week, for 4 weeks. Following WRS, MK-4 (30 mg/kg) was injected subcutaneously 3 times a week for 4 weeks. No growth retardation was observed in the WRS groups as compared with the control group. In the WRS groups, the BMD was significantly lower than that in the control group. The levels of bone formation and resorption markers were increased in the WRS groups, indicating that WRS reduced the BMD by promoting high bone turnover. A bone histomorphometrical examination showed that the trabecular (Tb) bone mass in the secondary spongiosa at the distal femur was significantly reduced in the WRS mice, and this reduction was abrogated by MK-4 treatment. Specifically, the Tb bone reduction was caused by the activation of osteoclasts (Ocs), and Oc activity was suppressed by MK-4. The number of osteoblasts and the mineral apposition rate were significantly increased in the WRS and WRS + MK-4 mice, suggesting that WRS triggered a significantly higher mineral apposition rate. These results indicate that MK-4 can induce recovery from the bone mineral loss caused by WRS treatment. Further studies are required to clarify the association between bone quality and MK-4.Keywords
This publication has 31 references indexed in Scilit:
- RETRACTION: Role of Angiotensin-(1–7) in Gastroprotection against Stress-Induced Ulcerogenesis. The Involvement of Mas Receptor, Nitric Oxide, Prostaglandins, and Sensory NeuropeptidesThe Journal of Pharmacology and Experimental Therapeutics, 2013
- New satiety hormone nesfatin-1 protects gastric mucosa against stress-induced injury: Mechanistic roles of prostaglandins, nitric oxide, sensory nerves and vanilloid receptorsPeptides, 2013
- Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal womenOsteoporosis International, 2013
- Tocotrienol Attenuates Stress-Induced Gastric Lesions via Activation of Prostaglandin and Upregulation of COX-1 mRNAEvidence-Based Complementary and Alternative Medicine, 2013
- Vitamin K supplementation does not prevent bone loss in ovariectomized Norway ratsNutrition & Metabolism, 2012
- Pregnane X receptor knockout mice display osteopenia with reduced bone formation and enhanced bone resorptionJournal of Endocrinology, 2010
- Efficacy of Menatetrenone (Vitamin K2) against Non-Vertebral and Hip Fractures in Patients with Neurological DiseasesClinical Drug Investigation, 2009
- Vitamin K and the Prevention of FracturesArchives of internal medicine (1960), 2006
- Analysis of the cold-water restraint procedure in gastric ulceration and body temperaturePhysiology & Behavior, 2004
- Inhibitory Effect of Vitamin K2 (Menatetrenone) on Bone Resorption in Ovariectomized Rats: A Histomorphometric and Dual Energy X-Ray Absorptiometric StudyThe Japanese Journal of Pharmacology, 1999